Armata Pharmaceuticals received an additional $3.7 million in non-dilutive Department of War funding for AP-SA02’s Phase 3 development. The money matters to investors because it is the program’s first Phase 3-specific support and lifts cumulative non-dilutive funding under the award to approximately $32.4 million.

Key Highlights

  • The latest $3.7 million commitment is designated for AP-SA02’s Phase 3 execution.
  • Cumulative non-dilutive Department of War support under the award has reached approximately $32.4 million.
  • AP-SA02 is being developed alongside antibiotics for complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA.

$3.7M Supports AP-SA02 Phase 3

Armata Pharmaceuticals, Inc. (AMEX: ARMP) is a biotechnology company. The new funding is the first Department of War support specifically tied to Phase 3 execution for AP-SA02. The program is being advanced for AP-SA02, an intravenously administered multi-phage product candidate intended as an adjunct treatment for complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive or methicillin-resistant S. aureus. The funding will support activities connected with the Phase 3 clinical program.

Phase 3 Study Expected in Second Half of 2026

The product candidate has received Qualified Infectious Disease Product, Fast Track and Breakthrough Therapy designations from the FDA. The new commitment extends Department of War support into the Phase 3 stage.